Xtl Biopharmaceuticals (XTLB) Change in Working Capital (2009 - 2016)

Xtl Biopharmaceuticals (XTLB) has reported Change in Working Capital for 6 consecutive years, with -$115000.0 the latest figure, recorded in Q2 2016.

• Quarterly Change in Working Capital fell 32.18% year-over-year to -$115000.0 in Q2 2016, while the trailing twelve-month figure through Jun 2016 was $1.5 million (up 399.68% YoY) and the FY2016 annual result came in at $1.0 million, down 58.11% from the prior year.
• Change in Working Capital fell to -$115000.0 in Q2 2016 per XTLB's latest filing, from $1.7 million in the prior quarter.
• Over the last five years, Change in Working Capital for XTLB reached as high as $2.3 million in Q4 2013 and fell as low as -$1.2 million in Q3 2013.
• A 4-year average of $350500.0 and a median of $109500.0 in 2014 frame the typical range for Change in Working Capital.
• The largest YoY upside for Change in Working Capital was 2864.29% in 2015 against a maximum downside of 143.28% in 2015.
• Year by year, Change in Working Capital stood at $2.3 million in 2013, then slumped by 97.54% to $56000.0 in 2014, then jumped by 2864.29% to $1.7 million in 2015, then slumped by 106.93% to -$115000.0 in 2016.
• According to Business Quant data, Change in Working Capital over the past three periods registered -$115000.0, $1.7 million, and $81000.0 for Q2 2016, Q4 2015, and Q3 2015 respectively.